SPDR S&P Pharmaceuticals ETF
XPH
XPH
74 hedge funds and large institutions have $141M invested in SPDR S&P Pharmaceuticals ETF in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
31% less capital invested
Capital invested by funds: $205M → $141M (-$64M)
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
Holders
74
Holding in Top 10
–
Calls
$883K
Puts
$297K
Top Buyers
| 1 | +$11.2M | |
| 2 | +$4.36M | |
| 3 | +$1.74M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.34M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.27M |
Top Sellers
| 1 | -$15.9M | |
| 2 | -$7.54M | |
| 3 | -$3.2M | |
| 4 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$2.6M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.49M |